Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialRafael Rosell, Ana Drozdowskyj, Enric Carcereny et al.|The Lancet Oncology|2012Cited by 5.5k
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung CancerHeather A. Wakelee, Jonathan Spicer, Moïshe Liberman et al.|New England Journal of Medicine|2023Cited by 1k
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trialMartin Reck, Anthony Lee, Yu Deng et al.|The Lancet Respiratory Medicine|2019Cited by 937
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trialJonathan Spicer, Marina Chiara Garassino, Heather A. Wakelee et al.|The Lancet|2024Cited by 233
Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cellsXiangnan Guan, Namrata S. Patil, Ruozhen Hu et al.|Nature|2024Cited by 121